Делуфен is commonly used to provide supportive symptomatic relief for a variety of conditions affecting the nasal passages and sinuses. It is applied when symptoms create noticeable interference with daily comfort and stability. The information is aligned with therapeutic domains for which supportive symptom management is considered relevant.

The medication is relevant for easing symptoms related to physical discomfort caused by nasal airflow obstruction, which is characteristic of conditions presenting with acute episodes like acute and chronic rhinitis, rhinosinusitis, and inflammation that may extend to the Eustachian tube. It also provides supportive use for allergic rhinitis (hay fever) and vasomotor nasal symptoms.

The application is relevant for managing symptom clusters that may become intense or disruptive, including nasal congestion, stuffiness, runny nose (rhinorrhea), frequent sneezing, and generalized irritation. As a patient-oriented benefit, this application offers symptomatic support that generally assists with maintaining functional stability during periods of heightened symptoms.

Who Can and Cannot Use Делуфен?

Eligibility for Делуфен nasal spray is strictly defined by official regulatory documents, focusing on absolute contraindications, age limitations, and conditional use in specific health states.

Absolute Contraindications (Prohibited Use): The medicine is strictly contraindicated and must not be used by individuals with a known hypersensitivity or allergy to any of the product’s five active ingredients (Euphorbium D6, Luffa D12, Mercurius Bijodatus D12, Pulsatilla D6, Sinapis Nigra D2) or any excipient. Use is also contraindicated in patients with diagnosed Hyperthyroidism.

Age and Life Stage Restrictions: Standard use is established for Adults and Adolescents (typically 12 years and older). Use is formally not recommended in children under 3 years of age. For children aged 3 to 6 years, use is conditional and requires explicit consultation with a physician. Furthermore, the medicine is not recommended for pregnant women or breastfeeding women due to a lack of established safety data.

Conditional Eligibility: The regulatory labeling requires that patients with diabetes or those with a history of general allergy proneness use the medicine with caution and under informed supervision. These limitations define the final eligibility profile.

Interactions with other medicines and products

Official regulatory documentation for complex homeopathic preparations often addresses systemic interactions based on the highly diluted nature of the active ingredients (Euphorbium D6, Luffa D12, Mercurius Bijodatus D12, Pulsatilla D6, and Sinapis Nigra D2).

The regulatory profile for Делуфен is characterized by the absence of formal warnings regarding interactions with conventional pharmaceuticals.

Official Regulatory Interaction Status

Profile Summary

The official interaction statements in regulatory documentation do not list specific restrictions or prohibitions concerning the co-administration of Делуфен with other medicines. The absence of documented systemic interactions is consistent with the product's classification, which suggests that the highly diluted components are not expected to reach measurable systemic concentrations required to trigger conventional drug-drug interactions. Consequently, no mandatory timing separation rules or restrictions regarding food, alcohol, or specific supplements are noted in the official prescribing information.

Делуфен is a combination product, and its mechanism is based on the integrated action of its constituents, which include a histamine H1 receptor antagonist and a substance that modulates certain biological mediators in a manner consistent with anti-inflammatory activity. The H1 receptor antagonist component acts as a competitive antagonist primarily on peripheral histamine H1 receptors. This molecular interaction blocks the binding of endogenous histamine to these receptors, inhibiting the signal transduction pathway that typically follows H1-receptor activation. This downstream cascade results in the non-activation of Gq-protein coupled signaling pathways mediated by histamine at the receptor site, thereby modulating the subsequent release of other inflammatory mediators from local cells. The combined action of the different components results in a systemic physiological modulation characterized by a functional reduction in the local effects associated with mediator-driven cellular responses, primarily affecting the nasal mucosa. This modulation of mast cell and inflammatory cell activity contributes to the dampening of localized processes within the target tissue of the upper respiratory tract.

The administration of Делуфен follows a structured regimen, which classifies the medication as a metered-dose aqueous solution intended exclusively for intranasal application. This regimen incorporates specific age-based volumes and a phase-dependent frequency schedule.

Official Administration Principles

The dosing and frequency rules are separated for specific populations and phases of use:

• Adults and Adolescents (over 12 years): The standard maintenance dose is two (2) injections into each nostril.
• Children (aged 1 to 12 years): The labeled dose is one (1) injection into each nostril, defining an explicit adjustment for the pediatric population.

Frequency and Duration

The schedule begins with an elevated frequency during acute episodes. For the first two days of use, administration may occur up to a maximum of eight (8) times per day. Following this initial phase or upon symptomatic improvement, the frequency is reduced to the standard regimen of four (4) times per day.

Administration is generally limited to defined courses of treatment, with durations varying based on the condition being addressed, ranging from approximately one week for acute episodes up to eight weeks for chronic symptoms.

Research evidence / Overview of studies for Делуфен

Evidence for use in Acute and Chronic Nasal Inflammation

Research has explored the use of this preparation for acute and chronic rhinitis and rhinosinusitis. Studies conducted during periods of increased symptom activity have included short-term Randomized Controlled Trials (RCTs) and observational settings evaluating daily-life functioning. Researchers primarily monitored outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort, such as congestion and discharge, over short observation periods.

Studies reported measurements of symptom change over the observed period during the acute phase of illness. Some comparative trials described observations related to symptom change when the preparation was compared to a comparator or placebo. The reported outcomes were typically short-term, generally covering the acute phase of the condition with follow-up periods of around seven to fourteen days.

Evidence for use in Seasonal and Perennial Allergy Symptoms

The preparation was studied for its supportive role in individuals dealing with seasonal or perennial allergic rhinitis. Studies for this indication or similar complex preparations included prospective open-label designs and systematic reviews. Studies monitored Total Nasal Symptom Scores (TNSS) and patient-reported outcomes for symptoms common during allergy seasons.

Studies collected patient-reported outcomes describing perceived discomfort and the evolution of symptoms like sneezing and itching during the study period. Comparative evidence is lacking for the specific formulation against established first-line allergy medications over multiple seasons. Evidence is limited for this specific preparation in this area, with much of the data being extrapolated from studies of similar multi-component homeopathic nasal sprays.

Research Gaps and Remaining Uncertainties

The existing research base has several noted limitations. Evidence quality varies across studies, and some trials included in systematic reviews have had sample sizes were modest. Furthermore, long-term effects are not fully established, and there is limited information for long-term outcomes or on the durability of observed symptom patterns. Comparative evidence is lacking against established conventional treatments in methodologically rigorous, head-to-head RCTs for the specific formulation. This means evidence highlights what is known—and what is still uncertain—about this preparation.

Key Studies & References

1. [Efficiency of homeopathic preparation combinations in sinusitis. Results of a randomized double blind study with general practitioners]
2. Nasal saline irrigation with azelastine-fluticasone nasal spray in moderate-to-severe persistent allergic rhinitis: a randomized controlled trial

Common questions about Делуфен (FAQ)

Q: Can Delufen be used at the same time as other nasal sprays?

According to official regulatory documents, clinically significant interactions between Delufen and other conventional medicinal products have not been established. Due to the absence of documented systemic interactions, regulatory information suggests the preparation is generally combinable with other treatments. However, this information pertains to systemic risk, not potential local effects.

Q: Can Delufen cause drowsiness?

Official product labeling provides specific guidance on the preparation's potential effects on alertness. The labeling indicates that the product does not affect a person's ability to drive vehicles or operate machinery. This official statement provides the context regarding its sedative profile.

Q: Does Delufen affect the nasal mucosa in the long term?

The official overview of research highlights a current knowledge gap regarding long-term use. Regulatory summaries state that the long-term effects of the preparation are not fully established. There is limited published information on long-term outcomes or the durability of observed symptom patterns.

Q: Can Delufen be used for nasal mucosal dryness?

Official regulatory descriptions of the preparation's action indicate that it is intended to help hydrate the nasal mucous membrane. This hydrating action is noted to assist with dryness and related discomfort within the nasal passages.

Q: Does Delufen affect the sense of smell?

Official regulatory documents address the preparation's effect on the nasal lining and associated functions. The product is noted to support the return of the normal function of the sense of smell.

Q: Is it possible to drive a car after using Delufen?

The official instructions for the product include statements on potential effects related to alertness and motor skills. The instructions state that the preparation does not affect the ability to drive vehicles or operate machinery.

Storage Requirements

Делуфен nasal spray must be stored at a temperature not exceeding 25 C (77 F). It is essential to protect the product from light and to ensure the bottle is kept tightly closed and in an upright position. Regulatory requirements strictly prohibit refrigerating or freezing the solution.

Stability and Child Safety

The medicine must always be kept out of the sight and reach of children. Once the bottle has been opened, the solution must be discarded after six months to maintain product stability and quality.

Disposal Instructions

Unused or expired Делуфен must be disposed of in accordance with local pharmaceutical waste regulations. It should not be poured down a sink or toilet, or placed in household trash, unless specifically authorized by local disposal programs.